Overexpression of progesterone receptor membrane component 1: Possible mechanism for increased breast cancer risk with norethisterone in hormone therapy

Menopause

Volumn 20, Issue 5, 2013, Pages 504-510

  Neubauer, Hans ^a   Ruan, Xiangyan ^b   Schneck, Helen ^a   Seeger, Harald ^a   Cahill, Michael A ^c   Liang, Yayun ^d   Mafuvadze, Benfor ^d   Hyder, Salman M ^d   Fehm, Tanja ^a   Mueck, Alfred O ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c CHARLES STURT UNIVERSITY   (Australia)

^d UNIVERSITY OF MISSOURI   (United States)

Author keywords

Breast cancer cells; Estradiol; Norethisterone; Progesterone receptor membrane component 1; Proliferative response

Indexed keywords

ESTRADIOL; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE; PGRMC1 PROTEIN; PLACEBO; PROGESTERONE; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER RISK; CELL PROLIFERATION; CELL STRAIN MCF 7; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HORMONAL THERAPY; HUMAN; HUMAN CELL; INOCULATION; MEMBRANE COMPONENT; MOUSE; NONHUMAN; PLASMID; TUMOR GROWTH; TUMOR VOLUME; VECTOR CONTROL;

ANIMALS; BREAST NEOPLASMS; CELL PROLIFERATION; CONTRACEPTIVES, ORAL, SYNTHETIC; DRUG THERAPY, COMBINATION; ESTRADIOL; ESTROGENS; FEMALE; GENE EXPRESSION; HUMANS; MCF-7 CELLS; MEDROXYPROGESTERONE ACETATE; MEMBRANE PROTEINS; MICE; MICE, NUDE; NORETHINDRONE; RECEPTORS, PROGESTERONE; TRANSFECTION; TUMOR BURDEN;

EID: 84879205121     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/gme.0b013e3182755c97     Document Type: Article

References (29)

1. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002; 288:321-333.
2. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 2004; 291:1701-1712.
3. Stefanick ML, Anderson GL, Margolis K.L., et al Effects of conjugated equine estrogens on breast cancer and mammography screening in post-menopausal women with hysterectomy. JAMA 2006; 295:1647-1657.
4. Seeger H, Mueck AO HRT and breast cancer caused: caused by pro-gestogens? Experimental vs. clinical data. J Steroid Biochem Mol Biol 2008; 109:11-15.
5. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008; 107:103-111.
6. Schoonen WGEJ, Joosten JWH, Kloosterboer HJ Effects of two classes of progestins, pregnane and 19-nortestosterone derivatives, on cell growth of human breast tumor cells: 1. J Steroid Biochem Mol Biol 1995; 55:423-437.
7. Cappelletti V, Miodini P, Fioravanti L., DiFronzo G. Effect of progestin treatment on estradiol-and growth factor-stimulated breast cancer cell lines. Anticancer Res 1995; 15:2551-2556.
8. Krämer E.A., Seeger H, Krämer B, Wallwiener D., Mueck AO The effect of progesterone, testosterone and synthetic progestogens on growth factor-and estradiol-treated human cancerous and benign breast cells. Eur J Obstet Gynecol Reprod 2006; 27:139-141.
9. Catherino WH, Jeng MH, Jordan VC Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism. Br J Cancer 1993; 67:945-952.
10. Franke HR, Vermes I. Differential effects of progestogens on breast cancer cell lines. Maturitas 2003; 46(SUPPL. 1):S55-S58.
11. Cahill MA. Progesterone receptor membrane component 1: an integrative review. J Steroid Biochem Mol Biol 2007; 105:16-36.
12. Meyer C, Schmid R, Scriba P.C., Wehling M. Purification and partial sequencing of high-affinity progesterone-binding site(s) from porcine liver membranes. Eur J Biochem 1996; 239:726-733.
13. Ahmed IS, Chamberlain C, Craven RJ S2R(Pgrmc1): the cytochrome-related R-2 receptor that regulates lipid and drug metabolism and hormone signaling. Expert Opin Drug Metab Toxicol 2012; 8:361-370.
14. Neubauer H, Clare SE, Wozny W, et al Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphor-ylation of PGRMC1. Breast Cancer Res 2008; 10:R85.
15. Neubauer H, Adam G, Seeger H., et al Membrane-initiated effects of progesterone on proliferation and activation of VEGF in breast cancer cells. Climacteric 2009; 3:230-239.
16. Peluso JJ. Progesterone signaling mediated through progesterone receptor membrane component-1 in ovarian cells with special emphasis on ovarian cancer. Steroids 2011; 76:903-909.
17. Munton RP, Tweedie-Cullen R, Livingstone-Zatchej M, et al Qualitative and quantitative analyses of protein phosphorylation in naive and stimulated mouse synaptosomal preparations. Mol Cell Proteomics 2007; 6:283-293.
18. Ahmed IS, Rohe HJ, Twist K.E., Craven RJ PGRMC1 (progesterone receptor membrane component 1) associates with EGFR and regulates erlotinib sensitivity. Biol Chem 2010; 285:24775-24782.
19. Mir SU, Ahmed IS, Arnold S, Craven RJ Elevated Pgrmc1 (progesterone receptor membrane component 1)/R-2 receptor levels in lung tumors and plasma from lung cancer patients. Int J Cancer 2012 131:E1-E9. doi:10.1002/ijc.26432.
20. Peluso JJ, Decerbo J, Lodde V. Evidence for a genomic mechanism of action for progesterone receptor membrane component-1. Steroids 2012 77:1007-1012.
21. Neubauer H, Yang Y, Seeger H., et al The presence of a membrane-bound progesterone receptor sensitizes the estradiol-induced effect on the proliferation of human breast cancer cells. Menopause 2011; 18:845-850.
22. Ruan X, Neubauer H, Yang Y., et al Progestogens and membrane-initiated effects on the proliferation of human breast cancer cells. Climacteric 2012 15:467-472.
23. Ruan X, Schneck H, Schultz S., et al Nomegestrol acetate sequentially or continuously combined to estradiol did not negatively affect membrane-receptor associated progestogenic effects in human breast cancer cells. Gynecol Endocrinol 2012; 28:863-866.
24. Liang Y, Besch-Williford C, Brekken R.A., Hyder SM Progestin-dependent progression of human breast tumor xenografts: a novel model for evaluating antitumor therapeutics. Cancer Res 2007; 67:9929-9936.
25. Mueck AO, Seeger H. The role of progestogens in breast cancer: experimental vs. clinical data. Menopausal Med 2006; 14:1-6.
26. Sitruk-Ware R. New progestogens for contraceptive use. Hum Reprod Update 2006; 12:169-178.
27. Sitruk-Ware R. Pharmacological profile of progestins. Maturitas 2004; 47: 277-283.
28. Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric 2005; 8(SUPPL. 1):3-63.
29. Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in post-menopausal women using estradiol-progestogen therapy. Obstet Gynecol 2009; 113:65-73.